Bastian BC - Search Results

1

MC1R variants increase risk of melanomas harboring BRAF mutations.

Fargnoli MC, Pike K, Pfeiffer RM, Tsang S, Rozenblum E, Munroe DJ, Golubeva Y, Calista D, Seidenari S, Massi D, Carli P, Bauer J, Elder DE, Bastian BC, Peris K, Landi MT. Fargnoli MC, et al. Among authors: bastian bc. J Invest Dermatol. 2008 Oct;128(10):2485-90. doi: 10.1038/jid.2008.67. Epub 2008 Mar 27. J Invest Dermatol. 2008. PMID: 18368129 Free PMC article.

2

Determinants of BRAF mutations in primary melanomas.

Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D, Bastian BC. Maldonado JL, et al. Among authors: bastian bc. J Natl Cancer Inst. 2003 Dec 17;95(24):1878-90. doi: 10.1093/jnci/djg123. J Natl Cancer Inst. 2003. PMID: 14679157

3

MC1R germline variants confer risk for BRAF-mutant melanoma.

Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, Calista D, Kanetsky PA, Pinkel D, Bastian BC. Landi MT, et al. Among authors: bastian bc. Science. 2006 Jul 28;313(5786):521-2. doi: 10.1126/science.1127515. Epub 2006 Jun 29. Science. 2006. PMID: 16809487

4

Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations.

Bauer J, Curtin JA, Pinkel D, Bastian BC. Bauer J, et al. Among authors: bastian bc. J Invest Dermatol. 2007 Jan;127(1):179-82. doi: 10.1038/sj.jid.5700490. Epub 2006 Aug 3. J Invest Dermatol. 2007. PMID: 16888631 Free article.

5

The prevalence and prognostic value of BRAF mutation in thyroid cancer.

Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A. Kebebew E, et al. Ann Surg. 2007 Sep;246(3):466-70; discussion 470-1. doi: 10.1097/SLA.0b013e318148563d. Ann Surg. 2007. PMID: 17717450 Free PMC article.

6

[DNA copy number changes in the diagnosis of melanocytic tumors].

Bauer J, Bastian BC. Bauer J, et al. Among authors: bastian bc. Pathologe. 2007 Nov;28(6):464-73. doi: 10.1007/s00292-007-0944-4. Pathologe. 2007. PMID: 17882420 German.

7

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.

Lutzky J, Bauer J, Bastian BC. Lutzky J, et al. Among authors: bastian bc. Pigment Cell Melanoma Res. 2008 Aug;21(4):492-3. doi: 10.1111/j.1755-148X.2008.00475.x. Epub 2008 May 29. Pigment Cell Melanoma Res. 2008. PMID: 18510589 No abstract available.

8

Improving melanoma classification by integrating genetic and morphologic features.

Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastian BC. Viros A, et al. Among authors: bastian bc. PLoS Med. 2008 Jun 3;5(6):e120. doi: 10.1371/journal.pmed.0050120. PLoS Med. 2008. PMID: 18532874 Free PMC article.

9

Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer.

Bauer J, Weng J, Kebebew E, Soares P, Trovisco V, Bastian BC. Bauer J, et al. Among authors: bastian bc. Exp Dermatol. 2009 Jun;18(6):548-52. doi: 10.1111/j.1600-0625.2008.00827.x. Exp Dermatol. 2009. PMID: 19493000 Free PMC article.

10

Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma.

Bauer J, Kilic E, Vaarwater J, Bastian BC, Garbe C, de Klein A. Bauer J, et al. Among authors: bastian bc. Br J Cancer. 2009 Sep 1;101(5):813-5. doi: 10.1038/sj.bjc.6605226. Epub 2009 Aug 4. Br J Cancer. 2009. PMID: 19654573 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

234 results

Search Page

Filters